Skip to main content

Nuvalent, Inc. (NUVL)

NASDAQ: NUVL · Delayed Price · USD
33.19 -2.51 (-7.03%)
Sep 21, 2021 4:00 PM EDT - Market closed
Market Cap1.55B
Revenue (ttm)n/a
Net Income (ttm)-26.70M
Shares Out46.82M
EPS (ttm)-0.57
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume283,920
Open35.49
Previous Close35.70
Day's Range33.00 - 36.89
52-Week Range17.00 - 40.82
Betan/a
Analystsn/a
Price Target42.00 (+26.5%)
Est. Earnings DateNov 15, 2021

About NUVL

Nuvalent is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We focus our discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. In particular, we focus on “clinically proven” kinase targets. We develop innovative small molecules that are designed to overcome the limitations of those existing therapies. By prioritizing target selectivity, we believe our drug candidates have ...

IndustryBiotechnology
IPO DateJul 29, 2021
CEOJames R. Porter, Ph.D
Employees27
Stock ExchangeNASDAQ
Ticker SymbolNUVL
Full Company Profile

Financial Performance

Financial Statements

News

Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., Sept. 8, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cance...

1 week ago - PRNewsWire

Monday Afternoon Analyst Upgrades and Downgrades: Chesapeake Energy, Traeger and More

With the trading day more than halfway over, the broad markets had a roaring start to the week with the S&P 500 and Nasdaq hitting record intraday highs.

Other symbols:CHKCOOKCADLRLYBRSKD
4 weeks ago - 24/7 Wall Street

Nuvalent Announces Closing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announce...

1 month ago - PRNewsWire

Nuvalent Announces Pricing of Initial Public Offering

/PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,...

1 month ago - PRNewswire

Hungry for more cash, Nuvalent files for customary $100M IPO 6 months after launching

Nuvalent has brought in $185 million through two funding rounds since launching in January, but the precision cancer biotech wants more: an IPO. Cambridge, Massachusetts-based Nuvalent filed Wednesday f...

2 months ago - FierceBiotech

Six months after launch, Cambridge cancer startup files for IPO

Deerfield Capital's latest cancer venture is raring to hit the public markets, just six months after emerging from stealth.

2 months ago - Boston Business Journal

Nuvalent IPO Registration Document (S-1)

Nuvalent, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC